TITLE

Costs and benefits of routine follow-up after curative treatment for endometrial cancer

AUTHOR(S)
Agboola, Olu O.; Grunfeld, Eva
PUB. DATE
October 1997
SOURCE
CMAJ: Canadian Medical Association Journal;10/01/97, Vol. 157 Issue 7, p879
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a study to examine the costs of routine outpatient follow-up after treatment of endometrial cancer, and to determine if after care leads to early detection of recurring cancer and survival. Design and setting of the research; Patients; Results and conclusion.
ACCESSION #
9710070770

 

Related Articles

  • The Costs of Caring: Who Pays? Who Profits? Who Panders? Fleck, Leonard M. // Hastings Center Report;May/Jun2006, Vol. 36 Issue 3, p13 

    Focuses on the increase in health care costs in the U.S. Problems resulting from the high costs of medications such as drop coverage of health insurance and distortion of healthcare priorities; Reason cited for increase in medical care cost; Cost-effectiveness of treatments for cancer; Forecast...

  • Cancer cost high in Germany.  // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p2 

    The article discusses research being done on the cost of cancer treatment in Germany. It references a study by M. Hartmann. R. Kath and C. Gundermann published in the March 2008 issue of "Onkologie." The researchers mentioned the association of cancer treatment with higher costs per year of life...

  • When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology. Greenberg, Dan; Earle, Craig; Chi-Hui Fang; Eldar-Lissai, Adi; Neumann, Peter J. // JNCI: Journal of the National Cancer Institute;1/20/2010, Vol. 102 Issue 2, p82 

    New cancer treatments pose a substantial financial burden on health-care systems, insurers, patients, and society. Cost–utility analyses (CUAs) of cancer-related interventions have received increased attention in the medical literature and are being used to inform reimbursement decisions...

  • Medical technology as a key driver of rising health expenditure: disentangling the relationship. Sorenson, Corinna; Drummond, Michael; Khan, Beena Bhuiyan // ClinicoEconomics & Outcomes Research;May2013, Vol. 5, p223 

    Health care spending has risen steadily in most countries, becoming a concern for decision-makers worldwide. Commentators often point to new medical technology as the key driver for burgeoning expenditures. This paper critically appraises this conjecture, based on an analysis of the existing...

  • An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK. Benedict, Ágnes; Cameron, David A.; Corson, Hélène; Jones, Stephen E. // PharmacoEconomics;2009, Vol. 27 Issue 10, p847 

    Background: Paclitaxel and docetaxel have been available for the treatment of metastatic breast cancer (MBC) since the 1990s. However, until very recently, comparisons between these two drugs have been difficult due to lack of direct comparative clinical evidence and differences in trial patient...

  • Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand. Praditsitthikorn, Naiyana; Teerawattananon, Yot; Tantivess, Sripen; Limwattananon, Supon; Riewpaiboon, Arthorn; Chichareon, Saibua; Ieumwananonthachai, Nantakan; Tangcharoensathien, Viroj // PharmacoEconomics;2011, Vol. 29 Issue 9, p781 

    Background: The Thai healthcare setting has seen patients with cervical cancer experience an increasing burden of morbidity and mortality, a stagnation in the performance of cervical screening programmes and the introduction of a vaccine for the prevention of human papillomavirus (HPV)...

  • Oxaliplatin versus irinotecan for elderly patients with colon cancer?  // PharmacoEconomics & Outcomes News;12/10/2011, Issue 643, p4 

    The article presents a study which found that treatment using oxaliplatin in elderly patients with stage IV colon cancer is more cost effective than using the irinotecan-based regimen.

  • DDAs unavailable to many US prisoners with HCV.  // PharmacoEconomics & Outcomes News;10/22/2016, Vol. 764 Issue 1, p14 

    The article presents an analysis on the used of inpatient, outpatient and prescription claims on the cost effectiveness of chemotherapy regimes for breast cancer patients in the U.S.

  • A systematic review of PET and PET/CT in oncology: A way to personalize cancer treatment in a cost-effective manner? Langer, Astrid // BMC Health Services Research;2010, Vol. 10, p283 

    Background: A number of diagnostic tests are required for the detection and management of cancer. Most imaging modalities such as computerized tomography (CT) are anatomical. However, positron emission tomography (PET) is a functional diagnostic imaging technique using compounds labelled with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics